Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DoorDash Inc (DASH) vs Twist Bioscience Corp (TWST) Price & Performance

DoorDash IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

DoorDash Inc vs Twist Bioscience Corp — how do they compare? DoorDash Inc trades at $211.99 (market cap $90.93B), while Twist Bioscience Corp trades at $122.96 (market cap $7.82B). The key difference: DoorDash Inc is far larger — about 11.6× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals.

DASHTWST
Market Cap
$90.93B$7.82B
Sector
Consumer CyclicalHealth
52-Week High
$281.74$124.88
52-Week Low
$146.60$24.16
Enterprise Value
$88.89B$7.75B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DoorDash Inc

DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.

DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DoorDash Inc

Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).

Read more on DASH

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST